Inhibition by forskolin of cytosolic calcium rise, shape change and aggregation in quin2-loaded human platelets  by Sage, S.O. & Rink, T.J.
Volume 188, number 1 FEBS 2803 August 1985 
Inhibition by forskolin of cytosolic calcium rise, shape 
change and aggregation in quin2-loaded human platelets 
S.O. Sage and T.J. Rink* 
The Physiological Laboratory, Downing Street, Cambridge, CB2 3EG, and *Smith, Kline and French Research Limited, 
The Frythe, Welwyn, AL.6 9AR, England 
Received 13 June 1985 
The adenylate cyclase stimulator forskolin was used to study the inhibitory effects of elevated CAMP on 
the activation of washed human platelets loaded with the fluorescent Ca 2+ indicator quin2. In the presence 
of 10 PM isobutylmethylxanthine forskolin inhibited rises in [Ca2+], evoked by thrombin and platelet-acti- 
vating factor (PAF) due to both Ca2+ influx and release from internal stores with similar potency. Aggre- 
gation evoked by thrombin and PAF was suppressed whilst partial shape-change p rsisted, even in the ab- 
sence of a measurable rise in [Caz+],. Forskolin did not affect the rise in [Cazf], evoked by CaZ+ ionophore; 
aggregation was suppressed but shape-change p rsisted. 
Platelet Calcium Fluorescent indicator Forskolin Shape-change Aggregation 
1. INTRODUCTION 
Agents which increase cyclic AMP [1,2] inhibit 
platelet responses to a wide range of agonists. A 
major effect of CAMP seems to be suppression of 
the generation of second messengers. The inhibi- 
tion by CAMP of an agonist-induced rise in [Ca”]i 
due to both Ca2+ influx and release from internal 
stores has been shown [3,4] as has inhibition of 
agonist-induced hydrolysis of inositol lipids [5,6]. 
We have used the diterpene compound for- 
skolin, which elevates platelet CAMP by direct ac- 
tivation of adenylate cyclase [7,8] to study further 
the effects of CAMP on Ca2+ rises induced by 
thrombin and PAF in the presence and absence of 
external Cat+. If the mechanisms or messengers 
Abbreviations: CAMP, adenosine 3 ’ 5 ’ -cyclic mono- 
phosphate; IBMX, isobutylmethylxanthine; PAF, 
platelet activating factor (1-0-alkyl-2-acetyl-sn-glyceryl- 
3-phosphorylcholine); [Ca’+]t, cytoplasmic free calcium 
concentration; DMSO, dimethyl sulphoxide 
for CaL+ influx and release from internal stores 
differ, one might expect CAMP to affect these 2 
responses differently. Similar inhibition of the 2 
responses could be suggestive of a common 
mechanism. The effects of CAMP on shape change 
and aggregation evoked by thrombin and PAF, 
recorded simultaneously with [Ca*+]i (reported by 
quin2), were also assessed. The effect of CAMP on 
processes beyond the mobilisation of Ca2+ were 
studied using the Ca2+ ionophore ionomycin. 
2. EXPERIMENTAL 
Human platelets were isolated from freshly 
drawn blood and loaded with approx. 1 mM quin2 
as in [9]. The cells were resuspended in a physio- 
logical saline of composition: 145 mM NaCI, 5 
mM KCI, 1 mM MgCL, 10 mM Hepes, 10 mM 
glucose, pH 7.4, at 37°C. Hirudin (0.05 units/ml) 
and apyrase (20 pg/ml) were added to prevent ac- 
tivation by residual traces of thrombin and ADP, 
respectively. Cells were pretreated with 100 FM 
aspirin to prevent the generation of prostaglandin 
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Fig. 1. Effect of forskolin and 10 FM IBMX on responses evoked by 20 ng/rnl PAF. Upper traces, quin2 fluorescence; 
lower traces, absorbance. In (a-c) 1 mM CaClz was added, in (d-f) 1 mM EGTA was added. IBMX was added 150 
s and forskolin 120 s before the agonist. 
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endoperoxides and thromboxanes. Prior to ex- 
perimental procedures the external [Ca”] was ad- 
justed by the addition of CaClz or EGTA (Fluka) 
as required and the cells were equilibrated at 37°C 
for about 5 min. 
Quin2 fluorescence was measured in a stirred, 
thermostatted cuvette in a Perkin-Elmer MPF44A 
spectrophotometer with excitation 339 nm and 
emission 500 nm as previously described [lO,ll]. 
The procedure for calibration of the fluorescence 
signal is detailed elsewhere [ 111. The absorbance of 
the cell suspension was recorded simultaneously 
with quin2 fluorescence. Shape change and ag- 
gregation were assessed from this turbidimetric 
trace [12]. The presence or absence of an 
(a) 
800- 
aggregatory response was verified by single-cell 
counting and microscopic examination for micro- 
aggregates. 
In inhibitory experiments the phosphodiesterase 
inhibitor IBMX (10pM) was added (from methanol 
stock) to enhance the effect of forskolin in ele- 
vating CAMP and to minimise the known effects of 
thrombin and PAF in inhibiting adenylate cyclase 
[ 13,141 over the period of activation. Cells were in- 
cubated with IBMX for 30 s before the addition of 
forskolin (Calbiochem, from DMSO stock) and 
left for a further 120 s before addition of agonist. 
Experiments were performed alternately in the 
presence of 1 mM Ca’+ and 1 mM EGTA. Throm- 
bin (Sigma) and PAF (Calbiochem) were added 
(b) 
7 
3 
60 
so 
o* 1 
- I 
T 
[ FORSKOLIN 1 JJM IFoRsKoLlNJ LlM 
(cl 
800- 
800_ 
F 
L30_ 
s 
a 
200_ 
0. t * 
1 I 0.01 0.1 1 10 lb0 
[ FOFtSKOUN] )A4 
80 
$0 I 
$0 
il i 
a 20 
i 
O\ 
0.01 
[F&OLIN] ‘p4 
10 100 
(d) 
-:-;\ 
Fig.2. Forskolin dose-inhibition curves in the presence of 10 PM IBMX. On response voked by (a) 0.5 units/ml 
thrombin in the presence of 1 mM external Ca’*; 
ng/ml PAF in the presence of 1 mM Ca2+; 
(b) 0.5 units/ml thrombin in the presence of 1 mM EGTA; (c) 20 
(d) 20 ng/ml PAF in the presence of 1 mM EGTA. Bars show SE of 3-5 
determinations. Curves generated by application of Allfit and Ploteasy programmes. 
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Fig.3. Effect of forskolin and 1OrM IBMX on responses voked by 200 nM ionomycin in the presence of 1 mM external 
Ca’+. Other conditions as for fig. 1. 
from aqueous stock, ionomycin (Squibb) was add- 
ed from DMSO stock. The maximum concentra- 
tion of DMSO was 0.1% (v/v) which was itself 
without effect. 
3. RESULTS AND DISCUSSION 
3.1. Effect of forskolin on changes in internal 
calcium produced by PAF and thrombin 
The upper traces of fig.1 show that PAF (20 
ng/ml) produces a rapid rise in [Ca’+]i to around 
600 nM in the presence of 1 mM external Ca*+ 
(fig.la). IBMX (10pM) has only a negligible effect 
on this response (98 +2% control; SE, n = 5), 
which is inhibited by rising concentrations of for- 
skolin in the presence of 10 PM IBMX (figs lb,c 
and 2a). 
In the absence of external Ca*+ PAF produces a 
small rise in [Ca*+]i (fig.ld). This response is 
slightly reduced by IBMX (10 PM) alone (to 
83 + 6% control; SE, n = 5) and is inhibited by in- 
creasing concentrations of forskolin in the presence 
of 1OpM IBMX (figs le,f and 2b). Dose-response 
curves for the effect of forskolin on the PAF- 
induced [Ca*+]i rise in the presence and absence of 
external Ca*+ (fig.2a,b) show the similar potency 
of forskolin in inhibiting both types of response. 
The ICSO values were 354 and 953 nM, respectively, 
which were not significantly different at the 0.05 
level (P = 0.17). 
Fig.2c and d shows dose-response curves for the 
effect of forskolin on the thrombin-induced Ca*+ 
rise in the presence and absence of external Ca*+. 
The potency of this compound was similar in in- 
hibiting both types of response; ICSO values were 
580 and 530 nM, respectively. 
The small rise in [Ca*+]i which occurs in the 
presence of very low external Ca*+ is attributed to 
release from internal stores, whilst the larger rise 
occurring on stimulation in the presence of a high 
(1 mM) external concentration is attributed largely 
to Ca2+ influx [4,1 I]. 
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The mechanisms by which agonists induce Cat+ 
influx and release from internal stores are uncer- 
tain. It is unlikely that influx occurs through 
voltage-sensitive channels and ligand-operated 
channels have been proposed [ 15,161. Inositol 
1,4,5trisphosphate (from agonist-induced hydro- 
lysis of phosphatidylinositol bisphosphate by phos- 
pholipase C) has been proposed as the mediator of 
internal release [17]. The same molecule could act 
at ligand-operated Ca2+ channels in the plasma 
membrane to cause influx. 
The forskolin dose-response curves reported 
here show similar inhibition of both Ca2+ influx 
and release from internal stores by thrombin and 
PAF. These results thus do not support (though, 
of course, cannot exclude) the idea of any dif- 
ference between the mechanisms of agonist- 
induced Ca2+ influx and release from internal 
stores. 
3.2. Effect of forskolin on shape change and 
aggregation 
The lower trace in fig.la shows that PAF in- 
duces aggregation in the presence of 1 mM external 
Ca2+. This response is unaffected by 10,~M IBMX. 
Concentrations of forskolin that (in the presence 
of 10 pM IBMX) inhibit PAF-induced rises in 
[Ca2+]i also inhibited aggregation, as assessed 
from absorbance and shown in fig. Ib,c. Single 
platelet counts and microscopic examination of the 
suspension confirmed that no microaggregates had 
been formed. Similar results were obtained with 
thrombin (not shown). 
PAF induces shape change in the presence and 
absence of external Ca2+ (fig. la,d). Concentra- 
tions of forskolin which (in the presence of 10,~M 
IBMX) completely inhibit aggregation fail to 
abolish completely shape change induced by PAF 
(fig.le,f). A partial response persists even in the 
absence of a measurable rise in [Ca2+]i (fig.lf). 
Similar data were obtained with thrombin (not 
shown). These results suggest that a 
Ca2 + -independent pathway for shape change ex- 
ists, as proposed previously from other experimen- 
tal protocols in which shape change occurs without 
a measurable rise in [Ca2’]i, and that this stimulus- 
response coupling mechanism is relatively resistant 
to the effects of CAMP. 
Substantial rises in [Ca2+]i evoked by the Ca2+ 
ionophore ionomycin (which by-pass the normal 
receptor process) are an effective stimulus, produc- 
ing shape change and aggregation (fig.3a). As ex- 
pected, IBMX and forskolin have no effect on 
ionomycin-induced Ca2+ transients (fig.3b,c) 
[3,18]. Concentrations of forskolin which (in the 
presence of 10 PM IBMX) suppress aggregation 
evoked by PAF and thrombin also inhibit aggrega- 
tion induced by ionomycin (fig.3c). This shows 
that CAMP not only suppresses the generation of 
the Ca2+ signal by natural agonists but also 
reduces the effectiveness of Ca2+ in producing the 
aggregatory response. Shape change was found to 
persist when ionomycin-induced aggregation was 
suppressed, demonstrating that CAMP is ineffec- 
tive in interfering with the ability of an adequate 
Ca2 stimulus to produce shape change. 
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